Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring, with a deal with U.S. biotech Earendil Labs stretching to $1.8 billion in potential payments.
Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring, with a deal with U.S. biotech Earendil Labs stretching to $1.8 billion in potential payments.
